Investigating Pseudomonas Susceptibility to Ceftolozane/tazobactam
JUL 22, 2017 | CONTAGION® EDITORIAL STAFF
Jason Pogue, PharmD, BCPS-ID, Clinical Pharmacist, Infectious Diseases, Sinai-Grace Hospital, explains his team’s study regarding the susceptibility of Pseudomonas isolates to ceftolozane/tazobactam.
Interview Transcript (slightly modified for readability)
“Our study was simple; it was kind of a big data-type study where we just looked at 80 different hospitals, and basically any time that any of those hospitals on a given isolate, tested one of their Pseudomonas isolates to ceftolozane/tazobactam, we looked at the in vitro susceptibilities; we wanted to see if it was active or not.
I think it’s important to keep in mind when you look at those data that there’s going to be a selection bias that comes with that, because we only test this drug, when we can’t use the other one; so, they’re going to be more resistant pathogens in general. But what we found was that even though the vast majority of those were resistant to other traditional beta-lactam therapies, over 80% of them were still susceptible to ceftolozane, and that actually included about 80% susceptibility against nearly 200 Pseudomonas isolates that were resistant to all of the other beta-lactam options. Once again, making the case that it is really an unmet need or a niche from that standpoint.”
DISCLOSURES: Jason Pogue is a Consultant for Merck, Allergan, Med Co, Shionogi, Zavante, Achaogen. This study was supported by a grant from Merck.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
We break down our top HIV news stories of 2017. Did you read them all?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512